Format

Send to

Choose Destination
Immunotherapy. 2009 Mar;1(2):281-8. doi: 10.2217/1750743X.1.2.281.

Bacillus Calmette-Guerin immunotherapy for urothelial carcinoma of the bladder.

Author information

1
Department of Urology, University of Iowa, 375 Newton Road, Iowa City, IA 52242, USA.

Abstract

Mycobacterium bovis bacille Calmette-Guerin (BCG) is one of the great success stories of immunotherapy as a treatment for superficial urothelial carcinoma of the bladder. Despite clinical effectiveness in over 50% of patients, the high incidence of local side effects and presence of nonresponders has led to efforts to improve the therapy. Recent advances have suggested a role for neutrophils and TNF-related apoptosis-inducing ligand (TRAIL) in the antitumor inflammatory response. Cell wall components of mycobacteria alone, lowered doses of BCG, and combination with cytokines have been studied as ways to improve the immune response associated with BCG and/or reduce toxicity. This review will discuss the clinical use of BCG, its proposed mechanism of action, and directions of future research to improve efficacy and decrease side effects.

KEYWORDS:

BCG; Guerin; TRAIL; bacillus Calmette; bladder cancer; neutrophil; urothelial carcinoma

PMID:
20046960
PMCID:
PMC2746687
DOI:
10.2217/1750743X.1.2.281
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center